Glatiramer acetate and interferon beta-1b: A study of outcomes among patients with multiple sclerosis

Advances in Therapy

Volumn 26, Issue 5, 2009, Pages 552-562

  Castelli Haley, Jane ^a   Oleen Burkey, Merrikay A ^a   Lage, Maureen J ^b   Johnson, Kenneth P ^c  

^a Teva Neuroscience Inc   (United States)

^b HealthMetrics Outcomes Research LLC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Glatiramer acetate; Interferon beta 1b; Medical costs; Multivariate analyses; Relapse; Retrospective study

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; RELAPSE; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; INSURANCE CLAIM REPORTING; INTERFERON-BETA; LEAST-SQUARES ANALYSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 73449114287     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0028-3     Document Type: Article

References (40)

1. E.M. Frohman T.C. Frohman D.S. Zee R. McColl S. Galetta 2005 The neuro-ophthalmology of multiple sclerosis Lancet Neurol 4 111 121 15664543 10.1016/S1474-4422(05)00992-0 (Pubitemid 40138926)
2. E.M. Frohman 2003 Multiple sclerosis Med Clin North Am 87 867 897 12834152 10.1016/S0025-7125(03)00008-7 (Pubitemid 36712843)
3. Multiple Sclerosis International Federation. About MS: what is MS? http://www.msif.org/en/about-ms/what-is-ms.html. Accessed October 6, 2008.
4. National Multiple Sclerosis Society. About MS: who gets MS? Available at http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index. aspx. Accessed October 6, 2008.
5. C.W. Noonan S.J. Kathman M.C. White 2002 Prevalence estimates for MS in the United States and evidence of an increasing trend for women Neurology 58 136 138 11781421
6. R.G. Richards F.C. Sampson S.M. Beard P. Tappendon 2002 A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models Health Technol Assess 6 1 73 12022938 1:STN:280:DC%2BD383os1Ortg%3D%3D
7. Multiple Sclerosis International Federation. About MS: introduction. http://www.msif.org/en/about-ms/index.html. Accessed October 6, 2008.
8. D. Parkin A. Jacoby P. McNamee P. Miller S. Thomas D. Bates 2000 Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life J Neurol Neurosurg Psychiatry 68 144 149 10644777 10.1136/jnnp.68.2.144 1:STN:280:DC%2BD3c7ht12gsw%3D%3D (Pubitemid 30245835)
9. N. Murphy C. Confavreux J. Haas 1998 Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group J Neurol Neurosurg Psychiatry 65 460 466 9771766 10.1136/jnnp.65.4.460 1:STN:280:DyaK1cvkt1Ojuw%3D%3D
10. Multiple Sclerosis International Federation. About MS: recognised treatment for MS. http://www.msif.org/en/about-ms/recognised-treat.html. Accessed October 6, 2008.
11. M.J. Tullman F.D. Lublin A.E. Miller 2002 Immunotherapy of multiple sclerosis-current practice and future directions J Rehab Res Dev 39 273 286
12. P. Calabresi 2007 Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose-is more better? Nat Clin Pract Neurol 3 540 541 17768411 10.1038/ncpneuro0612 (Pubitemid 47528026)
13. C.H. Pohlman B.M. Uitdehaag 2000 Drug treatment of multiple sclerosis BMJ 321 490 494 10.1136/bmj.321.7259.490
14. C.C. Ford K.P. Johnson R.P. Lisak H.S. Panitch G. Shifroni J.S. Wolinsky 2006 A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Mult Scler 12 309 320 16764344 10.1191/135248506ms1318oa 1:STN:280:DC%2BD28zltVKmtQ%3D%3D (Pubitemid 43827186)
15. K.P. Johnson B.R. Brooks J.A. Cohen 1998 Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group Neurology 50 701 708 9521260 1:CAS:528:DyaK1cXitlymsLs%3D
16. K.P. Johnson B.R. Brooks J.A. Cohen 1995 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial Neurology 45 1268 1276 7617181 1:STN:280:DyaK2Mzkt1eqtQ%3D%3D
17. O.A. Khan A.C. Tselis J.A. Kamholz 2001 A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy Mult Scler 1 349 353
18. J. Haas M. Firzlaff 2005 Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxoner) Eur J Neurol 12 4259 4431
19. A. Carra P. Onaha V. Sinay 2003 A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis Eur J Neurol 10 671 676 14641512 10.1046/j.1468-1331.2003. 00669.x 1:STN:280:DC%2BD3srmslWgtA%3D%3D (Pubitemid 38030877)
20. M. Sela D. Teitelbaum 2001 Glatiramer acetate in the treatment of multiple sclerosis Expert Opin Pharmacother 2 1149 1165 11583066 10.1517/14656566.2.7.1149 1:CAS:528:DC%2BD3MXlslWjtLg%3D (Pubitemid 32633717)
21. W.M. Davis 2000 Multiple sclerosis: continuing mysteriesand current management Drug Topics 144 93 102
22. A.M. Vallittu J. Peltoniemi I. Elovaara 2005 The efficacy of glatiramer acetate in beta-interferonintolerant MS patients Acta Neurol Scand 112 234 237 16146492 10.1111/j.1600-0404.2005.00464.x 1:STN:280:DC%2BD2MvnslKntw%3D%3D (Pubitemid 41337070)
23. L.A. Prosser K.M. Kuntz A. Bar-Or M.C. Weinstein 2004 Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis Value Health 7 554 568 15367251 10.1111/j.1524-4733.2004.75007.x (Pubitemid 39390836)
24. J. Chilcott C. McCabe P. Tappenden 2003 Modeling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis BMJ 326 522 525 12623909 10.1136/bmj.326.7388.522
25. J.D. Prescott S. Factor M. Pill G.W. Levi 2007 Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database J Manag Care Pharm 13 44 52 17269836
26. C. Bell J. Graham S. Earnshaw 2007 Cost-effectiveness of 4 immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data J Manag Care Phar 13 245 261
27. C.J. Phillips 2004 The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment Curr Opin CNS Drugs 18 561 574 10.2165/00023210-200418090-00002 (Pubitemid 38951779)
28. Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov/cpi. Accessed April 20, 2009.
29. D. Ollendorf E. Jilinskaia M. Oleen-Burkey 2002 Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population J Manag Care Pharm 8 469 476 14740608
30. A. Alonso M.A. Hernán 2008 Temporal trends in the incidence of multiple sclerosis: a systematic review Neurology 71 129 135 18606967 10.1212/01.wnl.0000316802.35974.34
31. National Multiple Sclerosis Society. About MS: epidemiology of MS. Available at http://www.nationalmssociety.org/about-multiple-sclerosis/whogets- ms/epidemiology-of-ms/index.aspx. Accessed October 8, 2008.
32. R. Marrie R. Horwitz G. Cutter T. Tyry D. Campagnolo T. Vollmer 2008 Comorbidity, socioeconomic status and multiple sclerosis Mult Scler 14 1091 1098 18728060 10.1177/1352458508092263
33. Miller A. Paroxysmal disorders. In: Burks JS, Johnson KP, eds. Multiple sclerosis: diagnosis, medical management, and rehabilitation. New York: Demos Medical Publishing, Inc.; 2000.
34. W. Pöllmann W. Feneberg 2008 Current management of pain associated with multiple sclerosis CNS Drugs 22 291 324 18336059 10.2165/00023210- 200822040-00003
35. P. Trouillas J. Courjon 2007 Epilepsy with multiple sclerosis Epilepsia 13 325 333 10.1111/j.1528-1157.1972.tb05267.x
36. K.P. Johnson B.R. Brooks C.C. Ford 2000 Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group Mult Scler 6 255 266 10962546 1:CAS:528:DC%2BD3cXmsFOgurg%3D
37. IFNB Multiple Sclerosis Study Groupthe University of British Columbia MS/MRI Analysis Group. 1995 Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial Neurology 45 1277 1285
38. G. Kobelt J. Berg D. Atherley O. Hadjimichael B. Jonsson 2006 Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA Neurology 66 1696 1702 16769943 10.1212/01.wnl.0000218309.01322.5c (Pubitemid 43964625)
39. K. Whetten-Goldenstein F.A. Sloan L.B. Goldenstein E.D. Kulas 1998 A comprehensive assessment of the cost of multiple sclerosis in the United States Mult Scler 4 419 425
40. i3. Data assets: better data matters. http://www.i3-global.com/ DataAssets. Accessed October 8, 2008.